Pfizer Exceeds Q4 Earnings Expectations with Strong Covid Product Sales and Cost Cuts

The pharmaceutical giant sees revenue growth and operational stability as Covid-related volatility diminishes.

Pfizer reported adjusted earnings of 63 cents per share for Q4 2024, surpassing analyst expectations of 47 cents per share.
Quarterly revenue reached $17.76 billion, driven by better-than-expected sales of Covid products, including $3.38 billion from the Comirnaty vaccine and $727 million from Paxlovid.
Cost-cutting measures implemented in 2024 have saved $4 billion to date, with additional savings of $500 million expected in 2025.
Non-Covid products, including cancer therapies from the Seagen acquisition and heart disease drugs like Vyndaqel, also contributed significantly to revenue growth.
Pfizer reaffirmed its 2025 guidance, projecting $61 billion to $64 billion in sales and adjusted earnings between $2.80 and $3 per share.